Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.

Black, C M

Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. [electronic resource] - British journal of rheumatology Sep 1998 - 952-60 p. digital

Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

0263-7103

10.1093/rheumatology/37.9.952 doi


Administration, Oral
Adult
Aged
Dose-Response Relationship, Drug
Double-Blind Method
Female
Humans
Iloprost--administration & dosage
Male
Middle Aged
Raynaud Disease--classification
Scleroderma, Systemic--complications
Treatment Outcome
Vasodilator Agents--administration & dosage